Drug maker Janssen will drop its long-running patent lawsuit against Alphapharm after the generic drug maker agreed to refrain from making products that allegedly infringe Janssen’s patents for its HIV drug Prezista.
Pay TV giant Foxtel has lost an appeal of an IP Australia decision refusing to revoke a trade mark by telco China Unicom after a failure of the trade mark office’s online filing system meant its law firm, Allens, missed the deadline for opposing the mark.
Kraft Foods has come up short in its high-stakes legal battle against Bega over the right to use its distinctive peanut butter trade dress in Australia, allowing Bega to maintain its hold on the $60 million per year stake in the peanut butter market which it acquired by purchasing Kraft unit Mondelez’s Australian and New Zealand business in 2017.
A Netherlands-based fashion company is challenging a decision by IP Australia to refuse a trade mark for its brand of high-end menswear named after the father of the modern Olympic Games.
Judgment is expected Wednesday in a high-stakes dispute between consumer giants Kraft and Bega over who owns the rights to the signature Kraft peanut butter trade dress in Australia.
German medical device company B. Braun Melsungen has dropped its appeal of a ruling invalidating three of its intravenous catheter patents and finding rival Becton Dickinson did not infringe the patents.
The Full Federal Court has dismissed appeals by both parties to a ruling that dismissed allegations of infringement of a patent for an industrial machine safety system that uses laser fields to detect hazards.
Energy drink giant Red Bull has won judgment against South Korea’s Bullsone in a battle over the auto parts company’s Australian trade mark for a leaping red and black bull.
After losing its fight for a temporary injunction, Sanofi-Aventis has dropped its patent lawsuit against Alphapharm over the generic drug maker’s plans to market a competing insulin injector pen in Australia.
A judge has refused an application by generic drug maker Juno Pharmacueticals to withdraw an admission in a battle with Millennium Pharmaceuticals over its cheap version of breakthrough cancer drug Velcade, denying Juno a potential defence to allegations of patent infringement.